Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Hubert C. Chua"'
Autor:
Ganapathi Iyer Parameswaran, Bethany A Wattengel, Hubert C Chua, Jessica Swiderek, Tom Fuchs, Michael T Carter, Laura Goode, Kathleen Doyle, Kari A Mergenhagen
Publikováno v:
Clinical Infectious Diseases. 76:e1335-e1340
Background Studies evaluating stroke following varicella zoster virus (VZV) infection are limited, and the utility of zoster vaccination against this phenomenon is unclear. This study aimed to determine the risk of stroke 30 days following zoster inf
Autor:
Hubert C Chua, Kady Phe
Publikováno v:
Open Forum Infectious Diseases. 9
Background Treatment options against Enterococcus spp., a common nosocomial pathogen, are limited due to intrinsic resistance to multiple antibiotics. Ampicillin is considered drug of choice if susceptible, but data comparing outcomes between ampicil
Autor:
Nhi Nguyen, Hubert C. Chua, Ty Drake, Jinhee Jo, Stefanie Anne Stramel, Nancy N. Vuong, Anne J. Gonzales-Luna, Kelsey Olson, null on behalf of the Houston Infectious Diseases Network
Publikováno v:
Journal of pharmacy practice.
Purpose: To summarize the most noteworthy infectious diseases (ID) pharmacotherapy articles published in peer-reviewed literature in 2021. Summary: Members of the Houston Infectious Diseases Network (HIDN) nominated articles that were deemed to have
Autor:
Hubert C. Chua, Vincent Tam
Publikováno v:
Open forum infectious diseases. 9(12)
Significant progress in previous decades has led to several methodologies developed to facilitate the design of optimal antimicrobial dosing. In this review, we highlight common pharmacokinetic/pharmacodynamic (PKPD) modeling techniques and their rol
Autor:
Anant P. Shah, Nicholas M. Smith, Harriet de Souza, Arthur Chan, Laura A Wilkinson, Thomas D. Nguyen, Kari A. Mergenhagen, Hubert C. Chua, David Z. D'Argenio
Publikováno v:
PharmacotherapyREFERENCES. 41(11)
Recent updates in the therapeutic drug monitoring (TDM) guidelines for vancomycin have rekindled interest in maximum a posteriori-Bayesian (MAP-Bayesian) estimation of patient-specific pharmacokinetic parameters. To create a versatile infrastructure